Avenzo and Gilead Partner to Test AVZO-021 and Trodelvy® in HR+/HER2- Metastatic Breast Cancer

Avenzo Therapeutics, Inc. has recently announced a collaborative agreement with Gilead Sciences, Inc. to investigate the safety and efficacy of AVZO-021 when combined with Gilead’s Trodelvy® (sacituzumab govitecan-hziy). This combination is being explored as a potential treatment for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.

Avenzo is a clinical-stage biotechnology company dedicated to developing advanced oncology therapies. The company is particularly focused on AVZO-021, an investigational CDK2 inhibitor that is believed to be potentially best-in-class. This inhibitor plays a significant role in cell cycle regulation and is currently being evaluated in a Phase 1 study in the United States for treating advanced solid tumors.

Athena Countouriotis, M.D., Co-founder, President, and CEO of Avenzo Therapeutics, expressed enthusiasm about the collaboration with Gilead. She highlighted the potential of AVZO-021 to provide new treatment options for patients and mentioned plans to initiate combination cohorts with both Trodelvy and CDK4/6 inhibitors in the Phase 1b portion of the ongoing study, scheduled to begin in the fourth quarter of 2024.

The agreement between Avenzo and Gilead stipulates that Gilead will supply Trodelvy for the combination study, which Avenzo will conduct and sponsor. Both companies will retain the development and commercial rights to their respective drugs, whether used as monotherapy or in combination therapies.

Trodelvy, a Trop-2 directed antibody-drug conjugate (ADC), is a trademark of Gilead Sciences, Inc. This drug is designed to target and deliver chemotherapy directly to cancer cells, thereby minimizing the impact on healthy cells.

Avenzo Therapeutics, headquartered in San Diego, California, continues to focus on its mission to develop next-generation oncology treatments. The lead candidate, AVZO-021, is being studied for its potential to inhibit CDK2 selectively and effectively, providing a novel approach to cancer therapy.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!